Somatostatin or octreotide (if somatostatin not available)
Norfloxacin PO or ciprofloxacin IV
Second Line
Erythromycin
Ceftriaxone
FOLLOW-UP DISPOSITION Admission Criteria
ICU admission for actively bleeding varices
Recent history of variceal bleeding
High risk for early rebleeding:
Age >60 yr, renal failure, initial hemoglobin count <8
Discharge Criteria
Nonbleeding varices
Issues for Referral
Continued hemorrhage requiring surgery or higher level of care
Liver transplant
FOLLOW-UP RECOMMENDATIONS
Timely outpatient GI follow-up:
Will need annual surveillance endoscopies
Medication and lifestyle modifications
PEARLS AND PITFALLS
Intubate early, especially in patients with hepatic encephalopathy or hemodynamic instability.
Begin prophylactic antibiotics prior to endoscopy. Improves survival
In US, octreotide has replaced vasopressin owing to better side-effect profile. If vasopressin is required, use IV nitroglycerin infusion concomitantly to reduce end-organ ischemia.
Control the airway prior to placement of balloon tamponade device, which provides only a temporizing measure prior to surgery or TIPS
Hematochezia in a hemodynamically unstable patient is an upper GI bleed until proven otherwise.
Consult your GI specialists early, since endoscopy is the 1st-line diagnostic and therapeutic procedure.
ADDITIONAL READING
Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007;102:2086–2102.
Nevens F. Review article: A critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage. Aliment Pharmacol Ther . 2004;20(suppl 3):18–22.
Sass DA, Chopra KB. Portal hypertension and variceal hemorrhage. Med Clin N Am . 2009;93:837–853.
See Also (Topic, Algorithm, Electronic Media Element)
Cirrhosis
Gastrointestinal Bleeding
CODES ICD9
456.0 Esophageal varices with bleeding
456.1 Esophageal varices without mention of bleeding
456.21 Esophageal varices in diseases classified elsewhere, without mention of bleeding
ICD10
I85.00 Esophageal varices without bleeding
I85.01 Esophageal varices with bleeding
I85.10 Secondary esophageal varices without bleeding
VASCULITIS Richard S. Klasco BASICS DESCRIPTION
Injury to the walls of blood vessels from inflammation:
Ischemia and necrosis
Aneurysms and hemorrhage
Immunopathologic mechanisms:
Deposition of circulating antigen–antibody complex and complement fixation
Cell-mediated hypersensitivity
Granulomatous tissue reaction from persistent inflammation and formation of epithelioid giant cells
The vasculitides represent a wide group of disorders:
Multisystem disease with constitutional symptoms and inflammatory lab indices
Secondary to another disorder or trigger, or primary if vasculitis is the principal feature and the cause is unknown
Multiple factors determine presentation:
The size of the affected blood vessels
The specific distribution, severity, and duration of the inflammation
Degree of permeability or occlusion of the affected vessels
1 out of 2,000 adults has some form of vasculitis
ETIOLOGY
Classification is evolving and is increasingly based on presence or absence of antineutrophil cytoplasmic antibodies (ANCA).
Traditional classification is based on vessel size.
Large vessel vasculitides:
Temporal (giant cell) arteritis:
Granulomatous arteritis of the aorta and its major branches often involving the temporal artery
Patients >50 yr
Takayasu arteritis:
Granulomatous inflammation of the aorta and its major branches
Usually occurs in patients <50 yr
Medium vessel vasculitides:
Polyarteritis nodosa (PAN):
Small- and medium-sized arteritis
Common distribution includes vessels supplying the muscles, joints, intestines, nerves, kidneys, and skin